- Reply to the Letter regarding “Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study”
-
Nouso K, Kariyama K
- KMID: 2553811
- J Liver Cancer.
- 2024 Mar;24(1):5-6.
- doi: 10.17998/jlc.2024.01.02
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study”
-
Kim J
- KMID: 2553810
- J Liver Cancer.
- 2024 Mar;24(1):3-4.
- doi: 10.17998/jlc.2023.12.04
-
- CITED
-
- Close
- SHARE
-
- Close
- Performance of HCC diagnosis in the KLCA-NCC guidelines: a closer look at MRI contrast agents and HCC imaging hallmarks
-
Min JH, Kim YK
- KMID: 2553812
- J Liver Cancer.
- 2024 Mar;24(1):7-8.
- doi: 10.17998/jlc.2023.10.08
-
- CITED
-
- Close
- SHARE
-
- Close
- Intrahepatic cholangiocarcinoma: histological diversity and the role of the pathologist
-
Komuta M
- KMID: 2553814
- J Liver Cancer.
- 2024 Mar;24(1):17-22.
- doi: 10.17998/jlc.2023.12.11
Intrahepatic cholangiocarcinoma (iCCA) is one of the primary liver cancers and presents with tumor heterogeneity. About 50% of iCCAs comprise actionable mutations, which completely change patient management. In addition, the... -
- CITED
-
- Close
- SHARE
-
- Close
- Metastatic papillary renal cell carcinoma with portal vein tumor thrombosis confirmed on blind liver biopsy
-
Kim H, Roh TH, Lee JS, Kim MS, Kim BK
- KMID: 2553823
- J Liver Cancer.
- 2024 Mar;24(1):113-117.
- doi: 10.17998/jlc.2023.11.05
Portal vein tumor thrombosis (PVTT) is an uncommon condition in which tumor cells expand into the vessels, causing blood clot formation in the portal vein. PVTT is mainly associated with... -
- CITED
-
- Close
- SHARE
-
- Close
- Radiofrequency for hepatocellular carcinoma larger than 3 cm: potential for applications in daily practice
-
Kim JH, Sung PS
- KMID: 2553809
- J Liver Cancer.
- 2024 Mar;24(1):1-2.
- doi: 10.17998/jlc.2024.02.13
-
- CITED
-
- Close
- SHARE
-
- Close
- Multidisciplinary approach for hepatocellular carcinoma patients: current evidence and future perspectives
-
Oh JH, Sinn DH
- KMID: 2553817
- J Liver Cancer.
- 2024 Mar;24(1):47-56.
- doi: 10.17998/jlc.2024.02.27
Management of hepatocellular carcinoma (HCC) is challenging due to the complex relationship between underlying liver disease, tumor burden, and liver function. HCC is also notorious for its high recurrence rate... -
- CITED
-
- Close
- SHARE
-
- Close
- Advancing Korean nationwide registry for hepatocellular carcinoma: a systematic sampling approach utilizing the Korea Central Cancer Registry database
-
Kim BH, Yun EH, Lee JH, Hong G, Park JY, Shim JH, Kim E, Kong HJ, Jung KW, Lim YS
- KMID: 2553818
- J Liver Cancer.
- 2024 Mar;24(1):57-61.
- doi: 10.17998/jlc.2024.03.03
Hepatocellular carcinoma (HCC) presents a substantial public health challenge in South Korea as evidenced by 10,565 new cases annually (incidence rate of 30 per 100,000 individuals), in 2020. Cancer registries... -
- CITED
-
- Close
- SHARE
-
- Close
- Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm?
-
Stefanini B, Ielasi L, Pallotta DP, Penazza S, Marseglia M, Piscaglia F
- KMID: 2553815
- J Liver Cancer.
- 2024 Mar;24(1):23-32.
- doi: 10.17998/jlc.2024.02.21
This review explores the evolution of cancer staging, focusing on intermediate hepatocellular carcinoma (HCC), and the challenges faced by physicians. The Barcelona Clinic Liver Cancer (BCLC) staging system, introduced in... -
- CITED
-
- Close
- SHARE
-
- Close
- Complications of immunotherapy in advanced hepatocellular carcinoma
-
Song YG, Yoo JJ, Kim SG, Kim YS
- KMID: 2553813
- J Liver Cancer.
- 2024 Mar;24(1):9-16.
- doi: 10.17998/jlc.2023.11.21
Immune checkpoint inhibitors (ICIs) are highly effective in cancer treatment. However, the risks associated with the treatment must be carefully balanced against the therapeutic benefits. Immune-related adverse events (irAEs) are... -
- CITED
-
- Close
- SHARE
-
- Close
- Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
-
Kim DY
- KMID: 2553824
- J Liver Cancer.
- 2024 Mar;24(1):622-70.
- doi: 10.17998/jlc.2024.03.13
Approximately 80% of hepatocellular carcinoma (HCC) cases arise in sub-Saharan Africa and Eastern Asia, following a similarly high prevalence of chronic hepatitis B virus (HBV) carriers in these regions. The... -
- CITED
-
- Close
- SHARE
-
- Close
- Liver resection in selective hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombosis improves prognosis
-
Lim M, Kim J, Rhu J, Choi GS, Joh JW
- KMID: 2553822
- J Liver Cancer.
- 2024 Mar;24(1):102-112.
- doi: 10.17998/jlc.2024.01.31
Background/Aim: Hepatocellular carcinoma (HCC) tumor thrombi located in the first branch of the portal vein (Vp3) or in the main portal trunk (Vp4) are associated with poor prognosis. This study... -
- CITED
-
- Close
- SHARE
-
- Close
- Current perspectives on radiotherapy in hepatocellular carcinoma management: a comprehensive review
-
Kim D, Kim JS
- KMID: 2553816
- J Liver Cancer.
- 2024 Mar;24(1):33-46.
- doi: 10.17998/jlc.2024.02.26
This review examines the transformative role of external beam radiotherapy (EBRT) in managing hepatocellular carcinoma (HCC), spotlighting the progression from traditional EBRT techniques to advanced modalities like intensity-modulated radiotherapy (RT),... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
-
Park J, Lee YB, Ko Y, Park Y, Shin H, Hur MH, Park MK, Lee DW, Cho EJ, Lee KH, Lee JH, Yu SJ, Kim TY, Kim YJ, Kim TY, Yoon JH
- KMID: 2553820
- J Liver Cancer.
- 2024 Mar;24(1):81-91.
- doi: 10.17998/jlc.2023.12.25
Background/Aim: Atezolizumab plus bevacizumab and lenvatinib are currently available as first-line therapy for the treatment of unresectable hepatocellular carcinoma (HCC). However, comparative efficacy studies are still limited. This study aimed... -
- CITED
-
- Close
- SHARE
-
- Close
- Additional nodules detected using EOB-MRI in patients with resectable single hepatocellular carcinoma: an implication for active treatment strategy
-
Kim NR, Rho SY, Navarro J, An C, Han DH, Choi JS, Kim MJ, Choi GH
- KMID: 2553821
- J Liver Cancer.
- 2024 Mar;24(1):92-101.
- doi: 10.17998/jlc.2024.01.25
Background/Aim: Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOBMRI) further enhances the identification of additional hepatic nodules compared with computed tomography (CT) alone; however, the optimal treatment for such additional nodules... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study
-
Kariyama K, Nouso K, Hiraoka A, Toyoda H, Tada T, Tsuji K, Ishikawa T, Hatanaka T, Itobayashi E, Takaguchi K, Tsutsui A, Naganuma A, Yasuda S, Kakizaki S, Wakuta A, Shiota S, Kudo M, Kumada T
- KMID: 2553819
- J Liver Cancer.
- 2024 Mar;24(1):71-80.
- doi: 10.17998/jlc.2023.09.11
Background/Aim: The aim of this study was to compare the therapeutic efficacy of ablation and surgery in solitary hepatocellular carcinoma (HCC) measuring ≤5 cm with a large HCC cohort database. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
